Sjögren’s Syndrome Caused by PD-1 Inhibition in a Lung Cancer Patient

In this report, we present a patient with metastatic non-small cell lung cancer who developed Sjögren’s syndrome secondary to immune checkpoint inhibition. This patient had a typical clinical presentation as well as biochemical signature, developing only 18 months after the start of treatment with P...

Descripción completa

Detalles Bibliográficos
Autores principales: Caeyman, Aaron, Vandekerckhove, Olivia, Pat, Karin, Wynants, Jokke, Weytjens, Karolien, de Wergifosse, Isabelle, Cuppens, Kristof
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10601759/
https://www.ncbi.nlm.nih.gov/pubmed/37900791
http://dx.doi.org/10.1159/000532098

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10601759/
https://www.ncbi.nlm.nih.gov/pubmed/37900791
http://dx.doi.org/10.1159/000532098

Ejemplares similares